Psoriasis is one of the most common chronic inflammatory skin diseases, affecting about 250,000 people in Austria. While ...
Dry skin, itching, and fiery eczema can be caused by allergens, stress, or an overactive immune response.Steroid creams ...
10d
First for Women on MSNLa La Anthony on Her Plaque Psoriasis: ‘It Doesn't Have To Hold You Back'Since revealing her plaque psoriasis diagnosis in 2015, La La Anthony has become a powerful voice for those living with the ...
Some patients with psoriasis may have a super response to guselkumab, but questions remain regarding the generalizability of treatment strategies.
10d
Medpage Today on MSNHumira Copycats for Psoriasis Backed by Real-World OutcomesIn a cohort of more than 11,000 patients from the U.K. and Ireland, a comparable proportion of new adalimumab users achieved ...
Bristol Myers Squibb has released new 5-year results from the long-term trial evaluating Sotyktu for the treatment of adults ...
Johnson & Johnson’s once-daily oral peptide has bested Bristol Myers Squibb’s reigning oral psoriasis med Sotyktu in a ...
Mar. 3, 2025 — Psoriasis is one of the most common chronic inflammatory skin diseases, affecting around 250,000 people in Austria. While previous treatment approaches have mainly focused on ...
Initiating methotrexate within 2 years of a psoriasis diagnosis is associated with a reduced risk of progressing to PsA.
"Psoriasis can be a challenging condition to manage due to long-term treatments with various side effects. SFA-002's effect in the imiquimod-induced mouse model is compelling. The results ...
Moreover, ICP-488 exhibited favorable safety and tolerability profiles, reinforcing its potential as a valuable treatment option for moderate-to-severe psoriasis patients. A total of 129 psoriasis ...
The latest news from AAD 2025 focused on psoriasis including abstracts, features, and helpful conference information.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results